MGC Pharmaceuticals gets approval for its cannabis dementia drug trial
http://news.marketsizeforecasters.com/mgc-pharmaceuticals-gets-approval-for-its-cannabis-dementia-drug-trial
- The company’s medical cannabis product, CogniCann, was granted approval to carry out the Phase IIB trials by Australia’s Therapeutic Goods Administration.
- The product has been specifically developed for treating dementia as well as memory loss in Alzheimer’s patients.
Leave a Reply